TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone978-552-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions
What is TransMedics Group's stock symbol?
TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."
How were TransMedics Group's earnings last quarter?
TransMedics Group Inc (NASDAQ:TMDX) released its earnings results on Wednesday, June, 12th. The company reported ($4.86) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.81) by $4.05. The firm had revenue of $4.68 million for the quarter, compared to analysts' expectations of $4.43 million. View TransMedics Group's Earnings History.
When is TransMedics Group's next earnings date?
What guidance has TransMedics Group issued on next quarter's earnings?
TransMedics Group updated its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $23.5-25.5 million, compared to the consensus revenue estimate of $24.52 million.
What price target have analysts set for TMDX?
4 equities research analysts have issued twelve-month price objectives for TransMedics Group's stock. Their forecasts range from $34.00 to $40.00. On average, they anticipate TransMedics Group's share price to reach $37.00 in the next year. This suggests a possible upside of 80.5% from the stock's current price. View Analyst Price Targets for TransMedics Group.
What is the consensus analysts' recommendation for TransMedics Group?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransMedics Group.
Has TransMedics Group been receiving favorable news coverage?
Media stories about TMDX stock have been trending negative recently, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TransMedics Group earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for TransMedics Group.
Who are some of TransMedics Group's key competitors?
Some companies that are related to TransMedics Group include Natus Medical (NTUS), Natus Medical (BABY), AxoGen (AXGN), Cutera (CUTR), Viewray (VRAY), BioLife Solutions (BLFS), Zynex (ZYXI), Semler Scientific (SMLR), Stereotaxis (STXS), Rockwell Medical (RMTI), Fonar (FONR), BioSig Technologies (BSGM), Fc Global Realty (FCRE), Second Sight Medical Products (EYES) and Edap Tms (EDAP).
What other stocks do shareholders of TransMedics Group own?
Who are TransMedics Group's key executives?
TransMedics Group's management team includes the folowing people:
- Dr. Waleed H. Hassanein, Pres, CEO & Director (Age 51)
- Mr. Stephen Gordon, CFO, Treasurer & Sec. (Age 51)
- Mr. John F. Carey, VP of Operations (Age 55)
- Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 48)
- Mr. Brian Thomson, VP of HR (Age 51)
When did TransMedics Group IPO?
(TMDX) raised $75 million in an IPO on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.
When does the company's lock-up period expire?
TransMedics Group's lock-up period expires on Tuesday, October 29th. TransMedics Group had issued 5,690,000 shares in its initial public offering on May 2nd. The total size of the offering was $91,040,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
Who are TransMedics Group's major shareholders?
TransMedics Group's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Abrams Capital Management L.P. (16.59%), Zimmer Partners LP (2.55%), Janus Henderson Group PLC (2.46%), Janus Henderson Group PLC (2.46%), BlackRock Inc. (1.53%) and Vanguard Group Inc. (1.46%). View Institutional Ownership Trends for TransMedics Group.
Which major investors are buying TransMedics Group stock?
TMDX stock was bought by a variety of institutional investors in the last quarter, including Abrams Capital Management L.P., Zimmer Partners LP, Janus Henderson Group PLC, Janus Henderson Group PLC, BlackRock Inc., Vanguard Group Inc., Emerald Advisers LLC and AXA. View Insider Buying and Selling for TransMedics Group.
How do I buy shares of TransMedics Group?
Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TransMedics Group's stock price today?
One share of TMDX stock can currently be purchased for approximately $20.50.
How big of a company is TransMedics Group?
What is TransMedics Group's official website?
How can I contact TransMedics Group?
TransMedics Group's mailing address is 200 MINUTEMAN ROAD, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]
MarketBeat Community Rating for TransMedics Group (NASDAQ TMDX)
MarketBeat's community ratings are surveys of what our community members think about TransMedics Group and other stocks. Vote "Outperform" if you believe TMDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TMDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
